Gilead Sciences Moves Ahead on Idelalisib Filings – OncLive
OncLiveGilead Sciences Moves Ahead on Idelalisib FilingsOncLiveCombination treatment with idelalisib and rituximab (Rituxan) was associated with a >70% improvement in overall survival (OS) in patients with high-risk relapsed/refractory CLL, accordin…
